H3 Biomedicine initiates dosing in Phase I trial of breast cancer drug

H3 Biomedicine, a member of Eisai ’s Oncology business group, has started dosing patients in a Phase I clinical trial of H3B-6545 as a monotherapy to treat breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news